Rating Change
Mizuho analysts reiterated a Outperform rating on Spyre Therapeutics, Inc. (NASDAQ:SYRE) on July 13, 2026.
reiterateNASDAQ:SYRE
Mizuho Reiterates Outperform Rating on Spyre Therapeutics, Inc. (SYRE)
Rating Change Mizuho analysts reiterated a Outperform rating on Spyre Therapeutics, Inc. (NASDAQ:SYRE) on July 13, 2026. Market Context Spyre Therapeutics, Inc.
Market Context
Spyre Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $93.73 with a market capitalization of $2.1B.
Analyst coverage from Mizuho provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Spyre Therapeutics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Spyre Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 13, 2026 | Mizuho | Outperform | N/A |
| Jun 23, 2026 | Deutsche Bank | Buy | N/A |
| Jun 15, 2026 | BTIG | Buy | N/A |
| Jun 04, 2026 | Deutsche Bank | Buy | N/A |
| May 06, 2026 | Stifel | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View SYRE Stock Page
Frequently Asked Questions
What does a Outperform rating mean for SYRE?
A Outperform rating from Mizuho reflects the analyst's outlook on Spyre Therapeutics, Inc. (NASDAQ:SYRE). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the SYRE forecast page.